Cellegy Announces 50 Percent Enrollment in HIV Prevention Trial in Ghana

Cellegy Pharmaceuticals has announced that 50 percent enrollment has been achieved in the Savvy Phase III HIV prevention trial in Ghana based on current projected enrollment.

This is a significant milestone reflecting the rapid accrual of a large number of trial participants. More than 1,500 women have enrolled in the trial, which first commenced enrollment in March 2004. Cellegy's Biosyn subsidiary is conducting two Phase III HIV prevention trials in Africa (Ghana and Nigeria).

The trials are placebo-controlled, double-blind studies that compare Savvy (C31G vaginal gel) with a placebo gel in women using the gels for 12 months. Women in both groups are strongly cautioned on safe sex practices and encouraged to have their partners use condoms. The primary endpoint of the studies is a 50 percent reduction in the rate of transmission of HIV in the Savvy group compared with the control. Cellegy is currently on track to have both trials completed in late 2006.